Compare PDX & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDX | KURA |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | NY | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.1M | 841.6M |
| IPO Year | N/A | 2015 |
| Metric | PDX | KURA |
|---|---|---|
| Price | $21.55 | $10.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.56 |
| AVG Volume (30 Days) | 85.5K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $18.47 | $5.45 |
| 52 Week High | $25.25 | $12.49 |
| Indicator | PDX | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 57.98 |
| Support Level | $21.50 | $8.80 |
| Resistance Level | $22.14 | $11.17 |
| Average True Range (ATR) | 0.30 | 0.63 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 56.44 | 55.25 |
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.